Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Sector: Services-Medical Laboratories
Industry: Medical - Diagnostics & Research
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 39.45M shares outstanding
USSera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present.
Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Gregory C. Critchfield, M.D., M.S.
Director
Jane F. Barlow, M.D.
Director
Jeffrey T. Elliott
Director
Joshua Phillips
Director
Employees
63
Country
US
Sector
Healthcare
Website
seraprognostics.com
Loading congressional disclosures…
based on 39.45M shares outstanding
US30d Avg
16.30K
60d Avg
20.45K
90d Avg
27.64K
